1Experts say it is crucial to ascertain the location and scale of potential faults, as well as areas prone to liquifaction before billions of dollars are poured in to the rebuilding of central Christchurch. Natural Hazards Manager for GNS Science, Kelvin Berryman, speaks to Nine To Noon about the need to map and understand faultlines before re-building parts of Christchurch.

2Many businesses in Christchurch's central business district are desperately trying to relocate to other parts of the city to keep their businesses afloat. Nine to Noon speaks with Simon Ironside an associate at Eliot Sinclair, a surveying and engineering firm in Christchurch which has had to find new premises, and Connal Townsend, Chief Executive of the Property Council of New Zealand.

3A New Zealand food science parternship between the Riddet Institute and Medicine Mondiale is aimed at creating a range of functional foods that improve global nutrition and reduce infant mortality rates.

4News from the United Kingdom, including: UK perspectives on Libya;

5Dr. Kenneth Hillan is the head of Roche Pharmaceuticals Asia-Pacific Clinical Development and Product Development Strategy. Switzerland-headquartered Roche is the world's largest biotechnology company and the largest maker of cancer drugs, and had global profits of $17-billion USD in 2010. The ability to purchase life changing drugs and new technologies is one of the greatest challenges facing health systems around the world. As the potential of new generation drugs swamps the capacity of government budgets to pay for them, New Zealand's own government drug buying agency Pharmac, comes under public pressure over its budget constraints and its drug funding choices even as it wins kudos for pushing down the price it pays to global drugs companies. As talks continue the for New Zealand to enter the Trans-Pacific partnership, there have been calls for it to be dismantled.